Acacia Research Corp (NASDAQ:ACTG) has been downgraded to Hold in a report by Zacks Investment Research today.
- Updated: September 28, 2016
Displaying a price of $6.54, Acacia Research Corp (NASDAQ:ACTG) traded 2.51% higher on the day. The last closing price is up 29.88% from the two hundred day moving average, compared to the S&P 500 which has decreased -0.01% over the same period. The company has recorded a 50-day moving average of $6.34 and a 200-day moving average of $5.04. 338,268 shares of Acacia Research Corp exchanged hands, down from an avg. volume of 502,438
Zacks Investment Research has downgraded Acacia Research Corp (NASDAQ:ACTG) to Hold in a statement released on Wednesday September 28, 2016.
On 7/29/2016, Barclays Capital released a statement about Acacia Research Corp (NASDAQ:ACTG) raised the target price from $4.00 to $6.00 that suggested an upside of 0.11%.
See Chart Below
Acacia Research Corp has a 52 week low of $2.82 and a 52 week high of $9.97 ACTG’s total market value is presently $0.
General Company Details For Acacia Research Corp (NASDAQ:ACTG)
Acacia Research Corporation, through its subsidiaries, is engaged in patent investment, prosecution, licensing and enforcement activities. The Company's subsidiaries partner with inventors and patent owners for patented inventions. The Company operates in patent licensing and enforcement business segment. The Company's subsidiaries generate revenues from the granting of intellectual property rights for the use of patented technologies that its subsidiaries control or own. The Company's subsidiaries assist patent owners with the prosecution and development of their patent portfolios, the protection of their patented inventions from unauthorized use, the generation of licensing revenue from users of their patented technologies and with the enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation. It is engaged in licensing and enforcing patented technologies. Its subsidiaries include Adaptix, Inc. and Body Science, LLC.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.